Myelodysplastic Syndromes (MDS) are a group of blood disorders that result from bone marrow dysfunction that may progress into acute leukemia. Until recently the mainstay of treatment was supportive care. ² Since the recent FDA approval of three new therapeutic drugs Dr. List says, “The way we manage anemia in patients with MDS has evolved from a strategy of managing the symptoms to one of active treatment of the underlying disease.” ³

In this compelling program we speak with specialists and patients to explore the challenges facing people who live with MDS and review the importance of reaching transfusion independence.